[17.11.2025] Seven researchers have received the ‘Highly Cited Researchers Awards 2025’ – an important signal for the international visibility and influence of research at the University of Duisburg-Essen. The award honours scientists whose publications are cited particularly frequently and who have also met other important scientific quality criteria over a period of eleven years. According to the Institute of Scientific Information at Clarivate Analytics, those included in this list are among the 6,868 people worldwide who have the greatest scientific influence.
ZMB Member: Prof. Dr. Alexander Probst
ZMB Member: Prof. Dr. Dirk Schadendorf
ZMB Member: Prof. Dr. Bernd Giebel
ZMB Member: Prof. Dr. Ken Herrmann
ZMB Member: Prof. Dr. Martin Schuler

[13.11.2025] Ein internationales Forschungsteam geht neue Wege im Kampf gegen Krebs des oberen Verdauungstrakts. Maßgeblich daran beteiligt sind Wissenschaftler:innen der Medizinischen Fakultät der Universität Duisburg-Essen. In ihrem Fokus stehen sogenannte Radionuklid-Theranostika. Das sind Medikamente, die Krebszellen gleichzeitig aufspüren und mit gezielter Strahlung zerstören können. Sie sollen in Zukunft auch bei Krebs des oberen Verdauungstrakts eingesetzt werden. Gefördert wird das Vorhaben von „Stand Up To Cancer“ für 18 Monate bis März 2027 mit rund 357.000 Euro. Rund 200.000 Euro fließen an die Forschenden in Essen.
ZMB Member: Prof. Dr. Ken Herrmann
ZMB Member: Prof. Dr. Katharina Lückerath

[10.11.2025] Unter dem Motto „FAIRe Daten – FAIR Play: Alles eine Frage der Aufstellung“ laden die Research Data Services (RDS) der UDE am 18. November zum 5. NRW-weiten Tag der Forschungsdaten mit einem abwechslungsreichen Programm ein.
Ab 10 Uhr übertragen wir im Bibliothekssaal am Campus Essen das Vormittagsprogramm der Landesinitiative fdm.nrw: In einer Podiumsdiskussion sprechen vier Forschende über ihre Arbeit in den Konsortien der nationalen Forschungsdateninfrastruktur (NFDI) – über Impact, über Beteiligungsmöglichkeiten und über die Zukunft des Forschungsdatenmanagements (FDM).
ZMB Member: Prof. Dr. Ralf Küppers

[13.10.2025] Else Kröner-Fresenius-Stiftung will fund a new research project starting in October 2025 that explores tumor-specific protein degradation strategies. The goal is to develop novel therapeutic approaches for head and neck cancers, including laryngeal carcinoma. The team led by Dr. Mike Blüggel at the Center of Medical Biotechnology (ZMB) is developing tailored nanobody-based PROTACs designed to selectively target the survival enzyme Survivin. Survivin plays a central role in the development of various cancers and contributes to resistance against radiation and chemotherapy. To date, it has remained difficult to reach therapeutically.
ZMB Member: Prof. Dr. Shirley Knauer

[13.10.2025] Scientists at the University of Duisburg-Essen are researching new therapies for aggressive forms of childhood leukaemia. For the first time, their approach tries to distinguish between two subtypes using so-called nanobody PROTACs. These attack diseased tissue while sparing healthy cells. The José Carreras Leukaemia Foundation is supporting the project, led by Prof. Dr. Shirley Knauer and Dr. Mike Blueggel from the Faculty of Biology, with 143,740 euros for two years.
ZMB Member: Prof. Dr. Shirley Knauer

[26.09.2025] DNA and RNA datasets in public repositories are expanding at an unprecedented pace, creating a global atlas of microbial diversity. While open access continues to drive research forward, it also presents a dilemma: painstakingly collected data are often made available worldwide before the researchers who generated them can publish their own findings. In response, an international consortium of more than 230 scientists, led by Professor Alexander Probst of the University of Duisburg-Essen, has published a roadmap in Nature Microbiology to promote fairer handling of public sequence data.
ZMB Member: Prof. Dr. Alexander Probst